Newron Pharmaceuticals (OTCMKTS:NWPHF – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations. Analyst Recommendations This is a breakdown of recent […]
Newron Pharmaceuticals (OTCMKTS:NWPHF – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations. Analyst Ratings This is a breakdown of recent […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) and Newron Pharmaceuticals (OTCMKTS:NWPHF – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 93.6% of Corcept Therapeutics […]
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR
Primary endpoint and key secondary endpoint of study met; drug was well tolerated, with no safety concerns identified
Glutamatergic inhibition mechanism.